Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BYM338

Known as: HuCAL-based Antibody BYM338, Human Combinatorial Antibody Library-based Monoclonal Antibody BYM338 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A global, randomized, double-blind placebo-controlled study was conducted to confirm that BYM338 (bimagrumab), an anti-activin… Expand
Is this relevant?
2017
2017
Significance We recently reported that activin type II receptors (ActRIIs) blockade using bimagrumab could positively impact… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
  • 2017
  • Corpus ID: 44484613
“This study illustrates that we have the potential to prevent muscle wasting and promote muscle growth in cell and animal models… Expand
Is this relevant?
2016
2016
Bimagrumab (BYM338) is a novel fully human monoclonal antibody that exerts strong promyogenic effects on skeletal muscle by… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2014
Highly Cited
2014
The myostatin/activin type II receptor (ActRII) pathway has been identified to be critical in regulating skeletal muscle size… Expand
Is this relevant?
Review
2014
Review
2014
INTRODUCTION Cachexia is a syndrome presenting with progressive unintentional weight loss and wasting and weakness of skeletal… Expand
Is this relevant?